Application of CRISPR Technology for Early Detection of Lung Cancer

Lung cancer is a disease with a high mortality rate that endangers human life and health. Due to the high late mortality rate, the early symptoms are not obvious, and the traditional diagnostic methods have misdiagnosis and missed diagnosis. However, the early diagnosis has limitations. Improving the accuracy of early screening for lung disease and reducing the harm to the human body is an important factor for improving the survival rate of lung cancer. At present, the combination of CRISPR-Cas system and cancer biomarkers has been proposed to achieve a non-invasive, convenient and accurate diagnosis. Tracing cancer biomarkers such as ctDNA and miRNA carry information from tumors, from which important information such as disease-related disease classification and disease staging can be obtained. Amplification technology amplifies the signal of tracing biomarkers and combines it with CRISPR technology. The precise cutting function of the CRISPR-Cas system can be used to present a fluorescent signal or a readable signal to enable the interpretation of disease information. In this research, the existing studies on CRISPR for lung cancer detection are summarized to help popularize relevant knowledge, and the prospect and prospect of CRISPR for lung cancer detection are discussed, hoping that better detection technology can be used for medical detection as soon as possible.